FindTrial
Sign In

Radical antegrade modular pancreatosplenectomy versus standard retrograde pancreatosplenectomy for T3 grade body and tail pancreatic adenocarcinoma: a multicenter real-world study

Radical antegrade modular pancreatosplenectomy versus standard retrograde pancreatosplenectomy for T3 grade body and tail pancreatic adenocarcinoma: a multicenter real-world study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091841
Enrollment
Unknown
Registered
2024-11-05
Start date
2024-11-15
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic adenocarcinoma

Interventions

Radical antegrade modular pancreatosplenectomy (RAMPS) group:None
Standard retrograde pancreatosplenectomy (SRPS) group:None

Sponsors

Fuzhou University Affiliated Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Postoperative pathology confirms that the tumor diameter is greater than 4 cm (T3NanyMany) in patients with pancreatic ductal adenocarcinoma (PDAC); (2) Patients with PDAC in the body and tail of the pancreatic treated with RAMPS or SRPS

Exclusion criteria

Exclusion criteria: (1) Patients with other concurrent malignancies; (2) Underwent neoadjuvant chemotherapy before surgery; (3) Death within 90 days after surgery; (4) Did not receive postoperative follow-up.

Design outcomes

Primary

MeasureTime frame
Recurrence-free Survival;—

Secondary

MeasureTime frame
Overall Survival;Postoperative Pancreatic Fistula;Postpancreatectomy Hemorrhage;Spleen vessels invasion;TP53 mutation;K-ras mutation;—

Countries

China

Contacts

Public ContactShi Chen

Fuzhou University Affiliated Provincial Hospital

wawljwalj@163.com+86 150 5918 6186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026